REGN Stock Summary and Trading Ideas (Regeneron Pharmaceuticals | NASDAQ:REGN)

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.

As of December 11, 2025, REGN stock price climbed to $746.80 with 1,069,032 million shares trading.

REGN has a beta of 0.72, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.09 to the broad based SPY ETF.

REGN has a market cap of $78.49 billion. This is considered a Large Cap stock.

Last quarter Regeneron Pharmaceuticals reported $4 billion in Revenue and $11.83 earnings per share. This beat revenue expectation by $161 million and exceeded earnings estimates by $2.99.

In the last 3 years, REGN traded as high as $1,211.20 and as low as $476.49.

The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, VOO, QQQ, SPY, IVV.

REGN has underperformed the market in the last year with a price return of -3.6% while the SPY ETF gained +15.5%. However, in the short term, REGN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +34.5% vs +5.9% return in SPY. But in the last 2 weeks, REGN shares have been beat by the market, returning -4.8% compared to an SPY return of +1.4%.

REGN support price is $708.55 and resistance is $743.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.